Drug Profile

Veligrotug - Viridian Therapeutics

Alternative Names: Anti-IGF1R monoclonal antibody - Viridian Therapeutics; AVE 1642; IMGN-164; LUMVOA; Veligrotug-vvze; VRDN 001; ZB 001; ZL-1108

Latest Information Update: 30 Jun 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ImmunoGen
Developer Sanofi; sanofi-aventis; Viridian Therapeutics; ZAI Lab
Class Antineoplastics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies
Mechanism of Action IGF type 1 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

29 Jun 2026 Planned Prescription Drug User Fee Act (PDUFA) date for Graves ophthalmopathy in USA (IV) is 2026-06-30
28 Jun 2026 No recent reports of development identified for phase-I development in Graves-ophthalmopathy in China (IV, Injection)
26 Jun 2026 Registered for Graves ophthalmopathy in USA (IV) - First global approval

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com